The approval is based on the STELLAR (NCT04576988) phase 3 trial comparing sotatercept-csrk with the placebo in combination with background standard of care therapies in adults with PAH.1
About The STELLAR Trial
Trial Name: A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)
ClinicalTrials.gov ID: NCT04576988
Sponsor: Acceleron Pharma Inc, a wholly-owned subsidiary of Merck & Co Inc
Completion Date: December 2022
In the study, 163 individuals received sotatercept-csrk and 160 received the placebo. Individuals were previously receiving stable background therapy and received either the placebo or the study drug every 3 weeks, according to the study authors. The primary endpoint was change from baseline at week 24 in 6-minute walking distance. The secondary endpoints included multicomponent improvement, change in pulmonary vascular resistance, change in N-terminal pro-B-type natriuretic peptide level, improvement in WHO functional class, time to death or clinical worsening, French risk score, and changed in Pulmonary Arterial Hypertension-Symptoms and Impact Physical Impacts (PAH-SYMPACT), Cardiopulmonary Symptoms, and Cognitive/Emotional Impacts domain scores.2
The results demonstrated that sotatercept-csrk and background therapy increased the 6-minute walking distance from baseline by 41 meters at week 24, according to the press release. Further, the combination therapy significantly improved multiple important secondary outcome measures, which included reducing the risk of death from any cause and clinical worsening events by approximately 84% when compared to background therapy alone.1
The first 8 secondary endpoints were significantly improved, except for PAH-SYMPACT Cognitive/Emotional Impact Domain scores, according to the study authors. Adverse events included epistaxis, dizziness, telangiectasia, increased hemoglobin levels, thrombocytopenia, and increased blood pressure.2
“New treatment options continue to be needed for patients with [PAH] that support important clinical goals, including increasing exercise capacity and improving functional class,” Aaron Waxman, executive director of the Center for Pulmonary Heart Diseases at Brigham and Women’s Hospital, said in the press release. “Sotatercept added to background therapy has the potential to become a new standard of care option for patients with [PAH].”1
The drug should be given ever 3 weeks by subcutaneous injections and may be administered by an appropriate patient or caregiver with guidance after training and follow-up from a health care provider, according to the press release. Previously, sotatercept-csrk was previously granted breakthrough designation.1
References
FDA Approves Merck’s Winrevair (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO Group 1). News release. Merck. March 26, 2024. Accessed March 27, 2024. https://www.merck.com/news/fda-approves-mercks-winrevair-sotatercept-csrk-a-first-in-class-treatment-for-adults-with-pulmonary-arterial-hypertension-pah-who-group-1/
Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388(16):1478-1490. doi:10.1056/NEJMoa2213558